rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
2006-11-24
|
pubmed:abstractText |
Activation of both beta(1)- and beta(2)-adrenoceptors increases the contractility of human atrial myocardium through cyclic AMP-dependent pathways. Cyclic AMP is hydrolised by phosphodiesterases, but little is known about which isoenzymes catalyse inotropically relevant cyclic AMP accumulated upon stimulation of beta-adrenoceptor subtypes. We have compared the positive inotropic effects of (-)-noradrenaline and (-)-adrenaline, mediated through beta(1)- and beta(2)-adrenoceptors, respectively, in the absence and presence of the PDE3 inhibitor cilostamide (300 nM) or PDE4 inhibitor rolipram (1 muM) on human atrial trabeculae from non-failing hearts. Cilostamide, but not rolipram, potentiated the effects of both (-)-noradrenaline and (-)-adrenaline. Cilostamide increased the -logEC(50)M of (-)-adrenaline more than of (-)-noradrenaline (P < 0.05), regardless of whether or not the patients had been chronically treated with beta-blockers. The results are consistent with a greater PDE3-catalysed hydrolysis of inotropically relevant cyclic AMP produced through beta(2)-adrenoceptors than beta(1)-adrenoceptors in human atrium.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3',5'-Cyclic-AMP Phosphodiesterases,
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic Nucleotide...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic Nucleotide...,
http://linkedlifedata.com/resource/pubmed/chemical/Epinephrine,
http://linkedlifedata.com/resource/pubmed/chemical/Norepinephrine,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Quinolones,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, beta-1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, beta-2,
http://linkedlifedata.com/resource/pubmed/chemical/Rolipram,
http://linkedlifedata.com/resource/pubmed/chemical/cilostamide
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0028-1298
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
374
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
249-53
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:17106669-3',5'-Cyclic-AMP Phosphodiesterases,
pubmed-meshheading:17106669-Adrenergic beta-Antagonists,
pubmed-meshheading:17106669-Aged,
pubmed-meshheading:17106669-Cyclic AMP,
pubmed-meshheading:17106669-Cyclic Nucleotide Phosphodiesterases, Type 3,
pubmed-meshheading:17106669-Cyclic Nucleotide Phosphodiesterases, Type 4,
pubmed-meshheading:17106669-Dose-Response Relationship, Drug,
pubmed-meshheading:17106669-Epinephrine,
pubmed-meshheading:17106669-Female,
pubmed-meshheading:17106669-Heart Atria,
pubmed-meshheading:17106669-Humans,
pubmed-meshheading:17106669-Hydrolysis,
pubmed-meshheading:17106669-Male,
pubmed-meshheading:17106669-Middle Aged,
pubmed-meshheading:17106669-Myocardial Contraction,
pubmed-meshheading:17106669-Myocardium,
pubmed-meshheading:17106669-Norepinephrine,
pubmed-meshheading:17106669-Phosphodiesterase Inhibitors,
pubmed-meshheading:17106669-Quinolones,
pubmed-meshheading:17106669-Receptors, Adrenergic, beta-1,
pubmed-meshheading:17106669-Receptors, Adrenergic, beta-2,
pubmed-meshheading:17106669-Rolipram
|
pubmed:year |
2006
|
pubmed:articleTitle |
Cilostamide potentiates more the positive inotropic effects of (-)-adrenaline through beta(2)-adrenoceptors than the effects of (-)-noradrenaline through beta (1)-adrenoceptors in human atrial myocardium.
|
pubmed:affiliation |
Department of Pharmacology and Toxicology, Dresden University of Technology, Dresden, Germany, christ@rcs.urz.tu-dresden.de.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
In Vitro
|